BCRX  Biocryst Pharmaceuticals Inc.

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.

769.4M

Vuru Grade

21.00/100

Current Price

$12.81
+0.56 (+4.57%)

Stability Price

$0.17
Overvalued by 98.66%

Company Metrics

  • 0 P/E
  • 42.69 P/S
  • 197.59 P/B
  • -0.623 EPS
  • -118.77% Cash ROIC
  • 2.49 Cash Ratio
  • 0 / 0% Dividend
  • 1.24M Avg. Vol.
  • 60.06M Shares
  • 769.4M Market Cap.

Company Description

BioCryst Pharmaceuticals, Inc. designs, optimizes, and develops small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. It uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry, and computer modeling to develop new therapeutic candidates. The com...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Use Options For a Chance To Buy BioCryst Pharmaceuticals at a 65% Discount
Forbes - Jul 28, 2014
Looking back to 61 days ago, BioCryst Pharmaceuticals BioCryst Pharmaceuticals, Inc. (NASD: BCRX) priced a $100,000,000 secondary stock offering at $10.00 per share.
Biotech Stocks Scanner -- Regeneron Pharma, BioCryst Pharma, Spectrum ...
MarketWatch - Jul 21, 2014
Although BioCryst Pharmaceuticals Inc.'s shares have declined 2.17% in the last three trading sessions, it has surged 35.37% in the previous three months and 48.55% on YTD basis.
BioCryst Pharmaceuticals Short Interest Up 39.9% in July (BCRX)
WKRB News - Jul 25, 2014
BioCryst Pharmaceuticals logo BioCryst Pharmaceuticals (NASDAQ:BCRX) was the target of a large increase in short interest in the month of July.
BioCryst Pharmaceuticals Sees Large Increase in Short Interest (BCRX) - Ticker Report
Eye Catching Stocks: BioCryst Pharmaceuticals (NASDAQ:BCRX), M/A-Com ...
WallStreet Scope - Jul 28, 2014
On 24 JULY BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) said that shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) were the target of a large growth in short interest in July.
BioCryst Pharmaceuticals Given Average Rating of "Buy" by Analysts (NASDAQ ...
WKRB News - Jul 7, 2014
BioCryst Pharmaceuticals logo BioCryst Pharmaceuticals (NASDAQ:BCRX) has earned a consensus rating of “Buy” from the twelve ratings firms that are currently covering the company, Analyst RN reports. Two analysts have rated the stock with a hold ...
News Buzz - Capstead Mortgage Corporation (CMO), BioCryst Pharmaceuticals ...
Techsonian (press release) - Jul 8, 2014
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) a biotechnology company, designs, optimizes, and develops small molecule pharmaceuticals that block key enzymes involved in the pathogenesis of diseases.
Mid Day Buzz: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), PPG Industries ...
Market News Call - Jul 1, 2014
BioCryst Pharmaceuticals, Inc.(NASDAQ:BCRX) disclosed HHS agreement expired on June 30, according to its terms and as a result of completion of activities funded under the Agreement (13.10 +0.35).
BioCryst Pharmaceuticals Given Consensus Recommendation of "Buy" by ...
Ticker Report - Jul 8, 2014
In other BioCryst Pharmaceuticals news, CFO Thomas R. Staab II sold 3,125 shares of the company's stock in a transaction that occurred on Tuesday, July 1st.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), Avino Silver & Gold Mines Ltd ...
Techsonian (press release) - Jul 3, 2014
Las Vegas, NV - 03 July 2014 - (Tech Sonian) - BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) showed 820,669 shares in volume during the last trading session, while the average trading volume remained 1.83 million shares.
Momentum Stocks in Focus - BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ...
Techsonian (press release) - Jul 9, 2014
Las Vegas, NV - July 09, 2014 - (TechSonian )- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) a biotechnology company, designs, optimizes, and develops small molecule pharmaceuticals that block key enzymes involved in the pathogenesis of diseases ...